Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

VSV based virotherapy in ovarian cancer: the past, the present and …future? J Cancer (2017) 0.75

Newcastle disease virus establishes persistent infection in tumor cells in vitro: contribution of the cleavage site of fusion protein and second sialic acid binding site of hemagglutinin-neuraminidase. J Virol (2017) 0.75

A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 12.86

Type I interferons in host defense. Immunity (2006) 7.32

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89

Oncolytic virotherapy. Nat Biotechnol (2012) 5.79

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72

Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44

Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol (2003) 2.21

Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10

Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol (1992) 2.01

The receptor of the type I interferon family. Curr Top Microbiol Immunol (2007) 1.94

Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol (2001) 1.92

The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. J Virol (1997) 1.87

Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol (2006) 1.82

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem (1997) 1.76

Persistent antigen presentation after acute vesicular stomatitis virus infection. J Virol (2006) 1.68

Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol (2006) 1.67

Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54

Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology (2004) 1.53

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res (1996) 1.41

Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev (2012) 1.38

Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol (2006) 1.34

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34

The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem (2008) 1.33

The role of differential expression of human interferon--a genes in antiviral immunity. Cytokine Growth Factor Rev (2009) 1.30

Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood (1998) 1.28

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 1.27

Binding and activity of all human alpha interferon subtypes. Cytokine (2011) 1.24

Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther (2012) 1.24

Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol (2009) 1.22

Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci (2008) 1.21

Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J Virol (2006) 1.18

Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther (2010) 1.18

Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J (2007) 1.14

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther (2010) 1.14

Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2012) 1.12

Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res (2002) 1.11

Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther (2003) 1.09

USP18 establishes the transcriptional and anti-proliferative interferon α/β differential. Biochem J (2012) 1.09

The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res (2003) 1.08

A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res (1992) 1.04

Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. J Leukoc Biol (2006) 1.03

IFN-alpha subtypes differentially affect human T cell motility. J Immunol (2004) 1.02

IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol (2013) 1.02

Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01

Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol (2006) 0.98

Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol (2008) 0.97

Matrix protein mutations contribute to inefficient induction of apoptosis leading to persistent infection of human neural cells by vesicular stomatitis virus. Virology (2002) 0.96

Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med (2010) 0.96

Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol (2011) 0.95

Correlation between interferon (IFN) alpha resistance and deletion of the IFN alpha/beta genes in acute leukemia cell lines suggests selection against the IFN system. Blood (1992) 0.93

Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer (2004) 0.93

Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine (2006) 0.90

Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther (2013) 0.90

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery (2012) 0.89

Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther (2011) 0.89

Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol (2011) 0.88

Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection. Antiviral Res (2002) 0.86

Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol (2013) 0.82

Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus. Mol Ther (2013) 0.81

Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Mol Ther (2013) 0.80

Vesicular stomatitis virus can establish persistent infections in Syrian hamsters. J Gen Virol (1982) 0.79

Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck (2014) 0.78

Oncolytic viruses: a new paradigm for treatment of head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol (2011) 0.75